Opioid Use in the Twenty First Century: Similarities and Differences Across National Borders

United Nations Office on Drugs and Crime. World Drug Report 2015 (United Nations publication, Sales No. E.15.XI.6). 2015. Retrieved from http://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf .

Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. “Every ‘Never’ I Ever Said Came True”: transitions from opioid pills to heroin injecting. Int J Drug Policy. 25(2), 257–66. doi: 10.1016/j.drugpo.2013.10.004

European Monitoring Centre for Drugs and Drug Addiction(EMCDDA). European drug report 2015: trends and developments. Luxembourg: Publications Office of the European Union; 2015. Retrieved from http://www.emcdda.europa.eu/edr2015 .

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Opioid trafficking routes from Asia to Europe. 2015. Retrieved from www.emcdda.europa.eu/topics/pods/opioid-trafficking-routes .

United Nations Office on Drugs and Crime. Drug Money: the illicit proceeds of opiates trafficked on the Balkan route. 2015. Retrieved from www.unodc.org .

European Monitoring Centre for Drugs and Drug Addiction(EMCDDA). European drug report 2013: trends and developments. Luxembourg: Publications Office of the European Union; 2013. Retrieved from http://www.emcdda.europa.eu/edr2013 .

Tarjan A, Dudas M, Gyarmathy VA, Rusvai E, Treso B, Csohan A. Emerging risks due to new injecting patterns in Hungary during austerity times. Subst Use Misuse. 2015;50(7):848–58. doi: 10.3109/10826084.2015.978672 .

Latypov A, Bidordinova A, Khachatrian A. IDPC Briefing paper—opioid substitution therapy in Eurasia: how to increase the access and improve the quality. 2012. IDPC Briefing Paper, January 2012. Retrieved from http://ssrn.com/abstract=2184370 .

United Nations Office on Drugs and Crime (UNODC). World Drug Report 2011. 2011. (United Nations Publication, Sales No. E.11.XI.10). Retrieved from www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf .

Russian Federal AIDS Center. HIV infections epidemiologic records in Russian Federation. 2014. Retrieved from http://www.hivrussia.ru/stat/index.shtml .

European Monitoring Centre for Drugs and Drug Addiction(EMCDDA). Regional drug strategies across the world: a comparative analysis of intergovernmental policies and approaches. Luxembourg: Publications Office of the European Union; 2014. Retrieved from http://www.emcdda.europa.eu/news/2014/fs4 .

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015. Retrieved from http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf .

Li X, Shorter D, Kosten TM. Prescription opioid misuse: effective methods for reducing the epidemic. Curr Treat Options Psych. 2015;2:122–35. doi: 10.1007/s40501-015-0045-6 .

Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician. 2007;10(3):399–424.

Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154–63. doi: 10.1056/NEJMra1508490 .

Manchikanti L, Helm 2nd S, Fellows B, Janata JW, Pampati V, Grider JS, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):Es9–38.

Centers for Disease Control and Prevention. Prescription painkiller overdoses: a growing epidemic, especially among women. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Retrieved from http://www.cdc.gov/vitalsigns/prescriptionpainkilleroverdoses/index.html .

Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821–6. doi: 10.1001/jamapsychiatry.2014.366 .

Mackey TK, Strathdee SA. Big events and risks to global substance using populations: unique threats and common challenges. Subst Use Misuse. 2015;50(7):885–90. doi: 10.3109/10826084.2015.983008 .

Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078–83. doi: 10.1073/pnas.1518393112 . This paper documents a marked increase in mortality and morbidity of middle-aged white non-Hispanic Americans, due in large part to increased rates from drug and alcohol poisonings.

Dom G, Samochowiec J, Evans-Lacko S, Wahlbeck K, Van Hal G, McDaid D. The impact of the 2008 economic crisis on substance use patterns in the countries of the European Union. Int J Environ Res Public Health. 2016;13(1). doi: 10.3390/ijerph13010122 .

UN Commission on Narcotic Drugs. Political declaration and plan of action on international cooperation towards an integrated and balanced strategy to counter the world drug problem. Vienna; 2009. Retrieved from https://www.unodc.org/unodc/commissions/CND/ .

Consortium IDP. The European Union Drugs Strategy 2013–2020. 2013. Retrieved from www.tni.org/files/IDPC-advocacy-note-EU-drug-policy-July-2013.pdf .

United States, Executive Office of the President, National Drug Control Strategy: Data Supplement 2014. Washington, D.C.; 2014.

Elovich R, Drucker E. On drug treatment and social control: Russian narcology’s great leap backwards. Harm Reduct J. 2008;5:23. doi: 10.1186/1477-7517-5-23 .

Mendelevich VD. Bioethical differences between drug addiction treatment professionals inside and outside the Russian Federation. Harm Reduction Journal. 2011;8(1):1–7. doi: 10.1186/1477-7517-8-15 .

Lunze K, Raj A, Cheng DM, Quinn EK, Bridden C, Blokhina E, Samet JH. Punitive policing and associated substance use risks among HIV-positive people in Russia who inject drugs. J Int AIDS Soc. 2014;17(1). doi: 10.7448/ias.17.1.19043 .

Ministry of Health of Russian Federation. Analysis of the state narcology system. 2014. Retrieved from http://www.rosminzdrav.ru/document/8177-prikaz-263-ot-05-06-2014-ob-utverzhdenii-kontseptsii-modernizartsii-narkologicheskoy-sluzhby (in Russian).

Strategy of state anti-drug policy of Russian Federation, 2010 – 2020. Retrieved from http://fskn.ru/pages/gak/4605/4604/strategy/index.shtml in Russian.

Gomez EJ, Harris J. Political repression, civil society and the politics of responding to AIDS in the BRICS nations. Health Policy Plan. 2016;31(1):56–66. doi: 10.1093/heapol/czv021 .

Lin Lu YF, Wang X. Drug abuse in China: past, present and future. Cell Mol Neurobiol. 2008;28(4):479–90. Retrieved from http://link.springer.com/article/10.1007%2Fs10571-007-9225-2 .

Luo T, Wang J, Li Y, Wang X, Tan L, Deng Q, et al. Stigmatization of people with drug dependence in China: a community-based study in Hunan province. Drug Alcohol Depend. 2014;134:285–9. doi: 10.1016/j.drugalcdep.2013.10.015 .

China National Center for AIDS Prevention and Control (NCAIDS). 2013. Annual Report.

Marienfeld C, Liu P, Wang X, Schottenfeld R, Zhou W, Chawarski MC. Evaluation of an implementation of methadone maintenance treatment in China. Drug Alcohol Depend. 2015;157:60–7. doi: 10.1016/j.drugalcdep.2015.10.001 .

Kelly BC, Liu T, Zhang G, Hao W, Wang J. Factors related to psychosocial barriers to drug treatment among Chinese drug users. Addict Behav. 2014;39(8):1265–71. doi: 10.1016/j.addbeh.2014.04.012 .

Zhang L, Chow EP, Zhuang X, Liang Y, Wang Y, Tang C, et al. Methadone maintenance treatment participant retention and behavioural effectiveness in China: a systematic review and meta-analysis. PLoS One. 2013;8(7):e68906. doi: 10.1371/journal.pone.0068906 .

Center for Substance Abuse Treatment. Detoxification and substance abuse treatment. Treatment Improvement Protocol (TIP) Series, No. 45. HHS Publication No.(SMA) 15–4131. Rockville: Center forSubstance Abuse Treatment; 2006. Retrieved from http://store.samhsa.gov/product/TIP-45-Detoxification-and-Substance-Abuse-Treatment/SMA15-4131 .

Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2004. 10.1002/14651858.CD004147.pub2(4) , Cd004147. doi: 10.1002/14651858.CD004147.pub2 .

Nosyk B, Li L, Evans E, Urada D, Huang D, Wood E, et al. Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991–2012. Drug Alcohol Depend. 2014;143:149–57. doi: 10.1016/j.drugalcdep.2014.07.020 . An examle of how despite general professional consensus about effective addiction treatment methods and multiple international and national guidelines, “detoxification” as a single treatment intervention continues to exist on a large scale.

Gowing L, Farrell MF, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2014;3:CD002024. doi: 10.1002/14651858.CD002024.pub4 .

Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009. 10.1002/14651858.CD002025.pub4(3) , Cd002025. doi: 10.1002/14651858.CD002025.pub4 .

Torban MN, Heimer RD, Ilyuk R, Krupitsky EM. Practices and attitudes of addiction treatment providers in the Russian Federation. J Addict Res Ther. 2011;2:104. doi: 10.4172/2155-6105.1000104 . A rare opportunity to see the Russian “narcological” treatment system for addictions through the eyes of addiction treatment professionals working in that system.

Ivanyets N, Tyulpin YG, Chirko VV, Kinkulkina MA. Psychiatry and narcology—in Russian. 2006.

Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2013;2:Cd003409. doi: 10.1002/14651858.CD003409.pub4 .

Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10(11):1727–40. doi: 10.1517/14656560903037168 .

Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP) Series 43. HHS Publication No. (SMA) 12–4214. Rockville: Substance Abuse and Mental Health Services Administration; 2005. Retrieved from http://store.samhsa.gov/product/TIP-43-Medication-Assisted-Treatment-for-Opioid-Addiction-in-Opioid-Treatment-Programs/SMA12-4214 .

Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146–57. doi: 10.1176/appi.ps.201300235 .

World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK143185/ .

WHO/UNODC/UNAIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper. 2004.

Harm Reduction International. The global state of harm reduction 2014. 2014. Retrieved from www.ihra.net .

DeFlavio JR, Rolin SA, Nordstrom BR, Kazal Jr LA. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019.

Feelemyer J, Des Jarlais D, Arasteh K, Abdul-Quader AS, Hagan H. Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. Addiction. 2014;109(1):20–32. doi: 10.1111/add.12303 . This article reveales the success of medication-assisted treatment (MAT) programs in low and middle-income countries. Many studies have documented retention in MAT programs in high income countries using a 50 % average retention rate at 12- month follow-up as a marker for success. This article shows the same retention rates in low and middle income countries.

Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04–3939. Rockville: Substance Abuse and Mental Health Services Administration; 2004. Retrieved from http://store.samhsa.gov/product/TIP-40-Clinical-Guidelines-for-the-Use-of-Buprenorphine-in-the-Treatment-of-Opioid-Addiction/SMA07-3939 .

Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146–50. doi: 10.1370/afm.665 .

Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39(2):96–104. doi: 10.1016/j.jsat.2010.05.004 .

Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12(5):448–53. doi: 10.1007/s11920-010-0135-5 .

Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66(10):1108–15. doi: 10.1001/archgenpsychiatry.2009.130 .

Kunoe N, Lobmaier P, Ngo H, Hulse G. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol. 2014;77(2):264–71. doi: 10.1111/bcp.12011 .

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–13. doi: 10.1016/s0140-6736(11)60358-9 .

Miller WR, Rollnick S. Motivational interviewing: helping people change. New York, NY: Guilford Press; 2013.

Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55(513):305–12.

Petry NM, Petrakis I, Trevisan L, Wiredu G, Boutros NN, Martin B, et al. Contingency management interventions: from research to practice. Am J Psychiatry. 2001;158(5):694–702. doi: 10.1176/appi.ajp.158.5.694 .

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).The role of psychosocial interventions in drug treatment. (Last update: 04.06.2015). Retrieved from www.emcdda.europa.eu/topics/pods/psychosocial-interventions .

National Institute on Drug Abuse(NIDA). Research report series—therapeutic communities. Revised July 2015. NIH Publication Number 15–4877.

National Institute on Drug Abuse. Research series: therapeutic communities. 2015. Retrieved from www.drugabuse.gov/publications/research-reports/therapeutic-communities/what-therapeutic-communitys-approach .

Bunt GC, Muehlbach B, Moed CO. The therapeutic community: an international perspective. Subst Abus. 2008;29(3):81–7. doi: 10.1080/08897070802218844 .

Sacks S, Banks S, McKendrick K, Sacks JY. Modified therapeutic community for co-occurring disorders: a summary of four studies. J Subst Abuse Treat. 2008;34(1):112–22. doi: 10.1016/j.jsat.2007.02.008 .

Wexler HK, Prendergast ML. Therapeutic communities in United States’ prisons: effectiveness and challenges. Ther Communities. 2010;31:157–75.

Sacks S, Sacks JY, McKendrick K, Pearson FS, Banks S, Harle M. Outcomes from a therapeutic community for homeless addicted mothers and their children. Adm Policy Ment Health. 2004;31(4):313–38.

De Leon G. Community as method: therapeutic communities for special populations and special settings. Westport: Praeger; 1997.

Dye MH, Roman PM, Knudsen HK, Johnson JA. The availability of integrated care in a national sample of therapeutic communities. J Behav Health Serv Res. 2012;39(1):17–27. doi: 10.1007/s11414-011-9251-1 .

Smith DE. The medicalization of therapeutic communities in the era of health care reform. J Psychoactive Drugs. 2012;44(2):93–5. doi: 10.1080/02791072.2012.684608 .

European Monitoring Centre for Drugs and Drug Addiction(EMCDDA). Therapeutic communities for treating addictions in Europe. Luxembourg: Publications Office of the European Union; 2014.